ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0938

Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity

Cecilia Nalli1, Daniele Lini2, Laura Andreoli2, Francesca Crisafulli2, Micaela Fredi2, Maria Grazia Lazzaroni2, Victoria Bitsadze3, Antonia Calligaro4, Valentina Canti5, Roberto Caporali6, Francesco Carubbi7, Cecilia Chighizola8, Paola Conigliaro9, Caterina De Carolis10, Teresa Del Ross4, Maria Favaro4, Maria Gerosa11, Annamaria Iuliano12, Jamilya Khizroeva3, Alexander Makatsariya3, Pierlugi Meroni13, Marta Mosca14, Melissa Padovan15, Roberto Perricone9, Patrizia Rovere-Querini16, Gian Domenico Sebastiani12, Chiara Tani14, Marta Tonello4, Dina Zucchi14, Franco Franceschini17 and Angela Tincani2, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, 2Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, 3Department of Obstetrics and Gynecology of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, 4Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy, 5Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy, 6Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 7Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, 8Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Experimental Laboratory of Immunorheumatological Researches, Istituto Auxologico Italiano, Milan, Italy, 9Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, 10Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, 11Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan, Italy, 12Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, 13Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, 14Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 15UO e Sezione di Reumatologia, Dipartimento di Scienze Mediche, Universita' degli Studi di Ferrara, Ferrara, Italy, 16Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Milan, Italy, 17Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy

Meeting: ACR Convergence 2020

Keywords: antiphospholipid syndrome, complement, pregnancy, risk factors, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Plenary Session II (0934–0939)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: The role of complement in the aPL related pathology has been widely studied in animal models. aPL can induce fetal loss in experimental animals but mice deficient in specific complement components (C4, C3, C5) appear somehow protected. In addition, in pregnant mice injected with aPL, antibody deposition has been found at decidual level causing focal necrosis, apoptosis and neutrophil infiltrates and supporting aPL pathogenetic potential. Instead, human studies did find hypocomplementemia associated to pregnancy complications in patients with obstetric APS. These results, however, are not unanimously confirmed and some studies only show increased levels of complement activation products (i.e. Bb) and not decreased levels of C3 and C4. This can be obviously due to methodological problems, challenging also because of the physiological alteration of complement profile during pregnancy. Recently low levels of C3 and/or C4 in early pregnancy and before pregnancy were found to significantly predict pregnancy complications and loss in a large cohort of primary APS. Therefore, we have thought that it would be interesting to investigate if the simple detection of low C3 and/or C4 could be considered a risk factor for adverse pregnancy outcome in obstetric APS and aPL carriers. 

Methods: We performed a multicentric study (487 pregnancies from 10 Italian Rheumatology Centers were included) and collected retrospectively data on pregnancies in women with primary APS (n=293) and aPL carriers with persistent antibody positivity (n=194). Serum C3 and C4 levels were evaluated by nephelometry; hypocomplementemia was defined by local laboratory reference values. Statistical analysis was performed using GraphPad.

Results: Preconceptional complement levels and gestational outcome were available for 96 (49%) aPL carriers pregnancies and 135 (46%) APS pregnancies. In patients with low preconceptional C3 and/or C4, a significantly higher prevalence of pregnancy losses was observed.(p=0.01). A subgroup analysis considered patients with triple aPL positivity. In this subgroup of high risk patients preconceptional low C3 and/or C4 levels were found associated with increased rate of pregnancy loss (p=0.04). On the other hand, in women with single or double aPL positivity, adverse pregnancy outcome was not found related to preconceptional complement levels (Table 1). To note, all pregnancy losses in the subgroup of triple aPL positivity were treated with low dose aspirin and low molecular weight heparin from the pregnancy test positivity. No relationship was found between low preconceptional complement levels and maternal complications (pre-eclampsia, eclampsia, deep vein thrombosis, thrombocytopenia).

Conclusion: Our findings confirm that decreased complement levels before pregnancy are associated with increased risk of adverse outcome in women with aPL, with or without APS. Even in the group of triple aPL positivity, considered per se at high risk, the presence of low C3 and/or C4 seems to predict a worse prognosis. Complement levels are cheap and easy to measure, therefore, they could represent a useful aid to identify patients with aPL at increased risk of pregnancy loss.


Disclosure: C. Nalli, None; D. Lini, None; L. Andreoli, None; F. Crisafulli, None; M. Fredi, None; M. Lazzaroni, None; V. Bitsadze, None; A. Calligaro, None; V. Canti, None; R. Caporali, AbbVie, Inc., 5, 8, Bristol-Myers Squibb, 5, 8, Eli Lilly, 5, 8, Gilead Sciences, Inc., 5, 8, Merck Sharp & Dohme, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8, Galapagos NV, 5, 8, Celgene, 5, 8; F. Carubbi, None; C. Chighizola, None; P. Conigliaro, None; C. De Carolis, None; T. Del Ross, None; M. Favaro, None; M. Gerosa, None; A. Iuliano, None; J. Khizroeva, None; A. Makatsariya, None; P. Meroni, None; M. Mosca, None; M. Padovan, None; R. Perricone, None; P. Rovere-Querini, None; G. Sebastiani, None; C. Tani, None; M. Tonello, None; D. Zucchi, None; F. Franceschini, None; A. Tincani, None.

To cite this abstract in AMA style:

Nalli C, Lini D, Andreoli L, Crisafulli F, Fredi M, Lazzaroni M, Bitsadze V, Calligaro A, Canti V, Caporali R, Carubbi F, Chighizola C, Conigliaro P, De Carolis C, Del Ross T, Favaro M, Gerosa M, Iuliano A, Khizroeva J, Makatsariya A, Meroni P, Mosca M, Padovan M, Perricone R, Rovere-Querini P, Sebastiani G, Tani C, Tonello M, Zucchi D, Franceschini F, Tincani A. Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/low-preconceptional-complement-level-is-related-with-an-adverse-obstetric-outcome-in-a-multicentric-cohort-of-pregnancy-in-patients-with-aps-and-apl-positivity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-preconceptional-complement-level-is-related-with-an-adverse-obstetric-outcome-in-a-multicentric-cohort-of-pregnancy-in-patients-with-aps-and-apl-positivity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology